Kornimate/medical-research-clean huggingface dataset:
carbohydrate loading in type 2 diabetes mellitus

Conditions: Diabetes Mellitus Type 2

Summary: the goal of this clinical trial is to learn the effects of preoperative carbohydrate loading on perioperative blood glucose levels and insulin resistance in type 2 diabetes mellitus undergo elective surgery. the main questions it aims to answer are: * does carbohydrate loading affects perioperative blood glucose and insulin resistance in type 2 diabetes mellitus patients undergo surgery? * how are the incident of perioperative hyperglycemia and hypoglycemia between subjects who receive placebo compared with subjects who receive carbohydrate loading * how are the hyperglycemia-related complications comparison between two groups? researchers will compare the carbohydrate loading intervention to placebo (regular drinking water with zero-calorie sweetener) to see the effects of carbohydrate loading to blood glucose levels and insulin resistance (by homa-ir value) participants will: * randomized to carbohydrate loading (cho) group or placebo * checked for preoperative, intraoperative, postoperative blood glucose, and preoperative and postoperative insulin level * evaluated for any hyperglycaemia-related complications


Eligibility criteria:
inclusion criteria: * controlled type 2 diabetes mellitus with any treatment * bmi \<30 kg/m2 * non-major elective surgery exclusion criteria: * subject refusal * geriatric patients with frailty score \>4 * subjects with critical illness * subjects received steroid treatment * subjects received total parenteral nutrition * subjects with intestinal obstruction * subjects with impaired liver function

Keywords: carbohydrate loading type 2 diabetes mellitus perioperative blood glucose insulin resistance
pola-zr2p in previously untreated dlbcl

Conditions: Diffuse Large B-cell Lymphoma

Summary: the goal of this phase 2 trial is to test the safety and efficacy of pola-zr2p as induction therapy in patients with dlbcl.

the investigators will evaluate safety and efficacy of pola-zr2p as induction therapy in previously untreated diffuse large b-cell lymphoma. orr(overall response rate, progression-free survival (pfs), overall survival (os), adverse events (aes) will be assessed.

Eligibility criteria:
inclusion criteria: * pathologically confirmed diffuse large b cell lymphoma according world health organization (who) classification; * patient is ≥ 18 years of age at the time of signing the informed consent form (icf). * patient must understand and voluntarily sign an icf prior to any study-specific assessments/procedures being conducted; * patient is willing and able to adhere to the study visit schedule and other protocol requirements; * patient has not received chemotherapy previously. * anticipated life expectancy at least 3 months exclusion criteria: * active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy. * pregnant or lactating women
longitudinal study in perimenopausal women with risk factors for atherosclerosis

Conditions: Atherosclerosis

Summary: the study hypothesis (or theory) is that monthly loss of iron before menopause may reduce women's risk of hardening of the arteries, or atherosclerosis. this study uses noninvasive, noncontrast magnetic resonance imaging (mri) of arteries in women entering menopause. this will help to determine if there is a correlation between iron accumulation and hardening of the arteries. in addition, blood levels of hormones will be measured to help show differences due to hormone levels vs. iron accumulation.

atherosclerosis, or hardening of the arteries, is the underlying disease responsible for the vast majority of cardiovascular morbidity and mortality and afflicted over 30 million americans in 2005. while the prevalence of atherosclerosis is similar in women and men, women enjoy a \~5-10 year lag in onset of cardiovascular events compared to men. after menopause, a state defined by marked reduction in ovarian hormone production, the incidence of events such as heart attack and stroke caused by atherosclerotic plaque rises up to threefold regardless of age range. this has prompted numerous investigations of hormone therapy (ht) to lower cardiovascular risk to premenopausal levels. therapeutic trials, however, have not realized a cardiovascular benefit; in fact, initiating ht in large randomized trials did not decrease and possibly increased cardiovascular risk. studies of coronary heart disease prevention have shown mixed results using estrogen alone vs. estrogen plus progestin, while studies of stroke prevention have consistently shown increased risk with ht. clearly, different therapeutic interventions warrant consideration. this proposal seeks to investigate a novel perspective using longitudinal clinical studies in women at risk of atherosclerosis. the studies involve a new noncontrast, noninvasive mri method with blood tests that measure cholesterol, hormone levels, and inflammation.

Eligibility criteria:
inclusion criteria: * women at least 40 yrs of age * between 1 and 6 menstrual cycles in the past 12 months * 2 or more of the following risk factors: high blood pressure, diabetes, high cholesterol, smoking * no known heart or vascular disease exclusion criteria: * any known cardiovascular disease such as coronary disease, peripheral vascular disease, heart failure * contraindication to mri scan (e.g. aneurysm clip, iron-containing metal) note that orthopedic hardware is usually mri-compatible. we will go over detailed screening before enrollment.

Keywords: hypertension diabetes smoking hyperlipidemia atherosclerosis risk
myfortic, prograf, and corticosteroids in de novo liver transplantation

Conditions: End Stage Liver Disease

Summary: the purpose of this study is to gather information regarding the use of myfortic, prograf, and corticosteroids in new liver transplant recipients. these three medicines help to prevent the body from rejecting the transplanted liver. the information the investigators are obtaining is data relating to the process of myfortic absorption by the body, its distribution in the body, the breakdown of myfortic in the body, and its elimination from the body. this absorption, distribution, breakdown, and elimination is called pharmacokinetics.

myfortic is approved for use in kidney transplant recipients, and has been prescribed by doctors for liver transplant recipients. no study has been reported to date evaluating the pharmacokinetics of myfortic in new liver transplant recipients who also take prograf and corticosteroids. during this six month study, a series of blood samples will be obtained after subjects take myfortic, prograf, and corticosteroids.

Eligibility criteria:
inclusion criteria: * adults \> or equal to age 18 years * planned to receive tacrolimus and corticosteroid therapy posttransplant * serum creatinine at transplant \< or equal to 2.5mg/dl * ucsf tumor staging \< 8cm total * females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the baseline visit and are required to practice a reliable method of contraception for the duration of the study and for no fewer than 6 weeks after completing the study. * signed informed consent form prior to any research assessment exclusion criteria: * induction therapy * requiring dialysis at the time of transplant * organ transplant other than liver * pregnant or nursing females * women of childbearing potential not practicing reliable methods of contraception. reliable methods for contraception include surgical sterilization (hysterectomy, bilateral tubal ligation), double-barrier method (such as condom and diaphragm). to be considered as post-menopausal and not of childbearing potential, female subjects must have experienced 12 consecutive months of amenorrhea. * require any medications that interfere with metabolism of myfortic (other than corticosteroids) * have a known hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or any of its excipients * participation in a study of investigational drug in the previous 30 days or 5 half-lives of the investigational drug

Keywords: myfortic mycophenolic acid prograf tacrolimus liver transplantation
eras in colorectal surgery diminishes the negative impact of sarcopenia on short term outcomes

Conditions: Sarcopenia; Colonic Neoplasms

Summary: so far, the impact of sarcopenia has been analysed only in patients undergoing traditional surgical procedures (laparotomy) or those with metastatic spread. as the eras protocol combined with minimally invasive access decreases postoperative metabolic disorders, it seems possible that it can limit the deleterious impact of sarcopenia as well. the aim of this study was to investigate whether the use of eras protocol in colorectal cancer patients influences the postoperative risk due to sarcopenia.

the prospective observation with post-hoc analysis of 171 consecutive colorectal cancer patients was performed. in all patients 16-item eras protocol was applied. contrast-enhanced ct scan was performed preoperatively. from each scan one ct image at the level of l3 vertebra was transferred in digital imaging and communications in medicine format (dicom) and anonymised. firstly, the threshold range between -29 and +150 hounsfield units was set to semi-automatically outline muscle areas, - 150 to - 50 was used for visceral adipose tissue areas, and -190 to -30 was used for subcutaneous and intermuscular adipose tissue areas. secondly, the software calculated the surface area (cm2) of each tissue. the l3 skeletal muscle area (rectus abdominis, external and internal obliques, transversus abdominis, quadratus lumborum, psoas, erector spinae) normalized for patient height was used to calculate skeletal muscle index (smi) (cm2/m2). according to martin et al. sarcopenia was defined as a smi \ 25 kg/m2 (10). to assess for myosteatosis the mean radiodensity of a l3 psoas muscle was measured. the cut-off for patients with bmi \<25 kg/m2 was \<41 hounsfield units and \<33 hounsfield units for patients with bmi ≥25 kg/m2. for the purposes of further analysis the entire group of patients was divided into subgroups depending on the presence of sarcopenia or myosteatosis.

Eligibility criteria:
inclusion criteria: * confirmed adenocarcinoma of colon or rectum * complete preoperative radiology assessment with abdominal ct scan * laparoscopic resection * perioperative care according to eras principles exclusion criteria: * unavailability of a preoperative abdominal ct scan (within 30 days prior surgery) * emergency or initially open surgery * patients treated with endoscopic techniques: transanal endoscopic microsurgery (tem), transanal total mesorectal excision (tatme) * concomitant inflammatory bowel diseases.

Keywords: sarcopenia myosteatosis enhanced recovery after surgery colorectal cancer minimally invasive surgery complications
efficiency of icotinib in plasma ctdna egfr mutation-positive patients diagnosed with lung cancer

Conditions: Plasma EGFR Mutation-positive Lung Cancer

Summary: this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib in plasma ctdna egfr mutation-positive patients diagnosed with lung cancer


Eligibility criteria:
inclusion criteria: * clinical diagnosis of peripheral lung cancer, but the pathological diagnosis is not yet clear. * plasma egfr mutations (egfr 19del and/or 21l858r) positive (simultaneously detected by super-arms, ddpcr and ngs，any positive). * unavailable of radical surgery or radical radiotherapy. * not previously received anticancer therapy like surgery, chemotherapy, radiation therapy, and biotherapy etc. * palliative radiotherapy for bone metastases is permitted, but there is no continuous toxicity associated with radiation therapy. * age 18-75 years old with performance status of 0 to 3. * with a measurable disease(longest diameters \>=10mm with spiral computed tomography (ct)) according to recist criteria.none of the lesions treated with radiotherapy could be used as target lesions. * adequate hematological, biochemical and organ functions. exclusion criteria: * severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases. * evidence of interstitial lung diseases * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study * other situations researchers think not appropriate to enter the group
chemoradiotherapy with elective low dose nodal radiation for locally advanced head and neck cancer

Conditions: Head and Neck Cancer

Summary: concurrent chemotherapy and radiation therapy (chemort) has become the standard of care for treatment of many patients with advanced head and neck squamous cell carcinoma (hnscc), though many clinical questions remain. prior experience has revealed locoregional control (lrc), disease free survival (dfs) and overall survival (os) at 3 years exceeding 80% after treatment with the use of hyperfractionated intensity modulated radiation therapy (imrt) and concurrent weekly cisplatin chemotherapy for patients with locally advanced hnscc. this multi-institutional phase ii zcc00204 trial resulted in an acceptable quality of life (qol) and toxicity profile. the current trial is an attempt to maintain high lrc, while further minimizing both acute and chronic toxicities, and maximizing qol.


Eligibility criteria:
inclusion criteria: * biopsy proven squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, or larynx * no surgical resection of primary site or neck dissection (excisional biopsy of lymph node is permitted) * human papilloma virus (hpv) testing of tumor performed; hpv p16 by immunohistochemistry * stage iii or iva disease (t1-2n1-3m0, t3-4n0-3m0) excluding t1-2n1 oral cavity and tonsil primaries and any n2c or bilateral n3 disease. patients with t2n0 cancer of the base of tongue and hypopharynx are eligible * ecog performance status 0-1 * age \>18 years * no current pregnancy * no other invasive malignancies within the last 2 years patients with basal cell or squamous cell skin cancers or carcinoma in situ of any site are eligible. * no prior radiotherapy to the head and neck region * no prior cisplatin chemotherapy * no symptomatic coronary disease or myocardial infarction within the last 6 months * laboratory evaluation: anc \> 2,000/mm3, platelets \>100,000/mm3, creatinine \ 50 ml/min, bilirubin \< 1.5 mg/dl, ast or alt \< 2x upper normal limit * study-specific consent signed prior to entry exclusion criteria: * second primary malignancy that is clinically detectable * inability or unwillingness to comply with chemort * prior radiotherapy, chemotherapy, or investigational treatment for squamous cell carcinoma of head and neck. * metastatic disease (m1) * pregnant or breast-feeding women.

Keywords: stg iii or iva squamous cell carcinoma. advanced
examining the effectiveness of digestive enzymes at reducing bloating and stomach distension

Conditions: Stomach Distended; Bloating

Summary: flatter me is a product that includes digestive enzymes in a way to support digestion of macronutrients and their constituents and provides herbs traditionally used for digestive health support. this trial aims to test flatter me against a placebo pill to examine differences in both subjective outcomes (feelings of bloating and indigestion) and changes in waist circumference (abdominal distension) after eating a test meal.


Eligibility criteria:
inclusion criteria: * self report bloating or stomach distension at least once per day after eating exclusion criteria: * females who are pregnant or breastfeeding * currently taking any prescribed medication meant to treat gut health * currently taking any medication for fluid balance (i.e., aldactone) * currently suffers from any pre-existing condition that would prevent them from adhering to the protocol. * currently suffers from any pre-existing condition that would prevent them from consuming cheese pizza. * use of an antibiotic in the previous 3 months. * taking an iron supplement with \> 65mg of iron in the last week. * diagnosed with any of ibs, chronic constipation, gerd, crohn's disease, ulcerative colitis, celiac disease, liver disease, kidney disease, heart failure. * lactose allergy or intolerance * any food allergies * current smoker * wears dentures

Keywords: digestion bloating
the effect of family counseling program on anxiety and conscious awareness levels

Conditions: Anxiety; Awareness; Family Therapy; Cognitive Behavioral Therapy

Summary: this study investigates the effect of a cognitive behavioral therapy (cbt)-based family counseling program on the anxiety and mindfulness levels of university students experiencing future anxiety. the research highlights the significance of university education in career development, noting the associated biopsychosocial challenges faced by students. these challenges often manifest as future anxiety-a condition characterized by fear, uncertainty, and stress about future prospects, which can impact students' academic performance, social relationships, and overall mental health. literature reveals that interventions like cbt, mindfulness practices, and family counseling are effective in managing anxiety and enhancing emotional resilience. the program integrates these approaches to provide dual-layer support, addressing individual thought patterns and family dynamics, thus potentially reducing anxiety and increasing mindfulness among students. this study aims to provide a comprehensive understanding of the program's effectiveness in a controlled setting, contributing to both national and international literature on mental health interventions.

this research was conducted as a pre-test, post-test randomized controlled study to determine the effects of a cognitive behavioral therapy (cbt)-based family counseling program on anxiety and mindfulness levels in university students experiencing future anxiety. the study collected data from 20 students, divided equally between 10 participants in the intervention group and 10 in the control group. data were gathered using a personal characteristics form, the future anxiety scale for university students, and the turkish version of the mindfulness awareness scale for adolescents and adults. the intervention group participated in an online cbt-based family counseling program, which was conducted weekly for 8 weeks, each session lasting between 50-60 minutes. for the first 6 weeks, the sessions included only the students, while the last two weeks also involved family members' participation. no intervention was applied to the control group. both groups were assessed with the aforementioned scales before the intervention and after its conclusion. this study aims to provide insights into the effectiveness of integrating family dynamics into therapeutic practices for reducing anxiety and enhancing mindfulness among students.

Eligibility criteria:
inclusion criteria: * the level of future anxiety is above 40 points * no problems with speech, perception or hearing * the person or persons who will be included in the study from family members will be able to participate in the online session at the time required for counseling * the student will regularly participate in the interview sessions to be held
comparison of ram cannula nasal continuous positive airway pressure versus infant flow nasal continuous positive airway pressure (ncpap)

Conditions: Acute Respiratory Deficiency; Prematurity; Assisted Ventilation

Summary: this study is designed to compare the effectiveness and ease of use of two commonly used ncpap interfaces: the ram nc and the infant flow prongs and nasal mask.


Eligibility criteria:
inclusion criteria: * less than or equal to 7 kg * order for nasal continuous positive pressure exclusion criteria: * patients greater than 7kg * patients that do not have informed consent
comparison study of wound closure at time of cesarean delivery: dermabond glue versus surgical staples

Conditions: Cesarean Section

Summary: women who have a cesarean delivery have a surgical incision on their abdomen (belly). the usual way to close this opening is with metal surgical staples. in many other types of surgery, surgical incisions are closed with a super-glue called dermabond. the researchers at the university of massachusetts believe dermabond may be a safe alternative to using staples at the time of a cesarean delivery, but this has not been studied. women who choose to participate will be randomly assigned to have the cesarean delivery skin incision closed with staples or dermabond. the researchers will survey the patients to see how they felt about the experience and the appearance of their scar. the researchers will survey physicians performing the surgery to see how easy dermabond was to use. the researchers will ask physicians to evaluate the appearance of the incision after a 6-week recovery period and will analyze complications (such as bruising, infection, or separation of the wound) in the two groups.


Eligibility criteria:
inclusion criteria: * pregnant women undergoing scheduled and non-scheduled cesarean deliveries exclusion criteria: * prisoners * insulin-requiring diabetics * vertical skin incision * allergy to dermabond

Keywords: cesarean wound dermabond superglue staples wound complications
a study of pts for patients with solid tumors

Conditions: Solid Tumor

Summary: the primary objective of this study is to determine the mtd of pts following local and intratumoral injections over a treatment course of two 5-day cycles to patients with palpable advanced solid malignancies who have failed standard treatment.

the study will be an open, uncontrolled, single-center, phase i study to assess the safety and tolerability of local intra-tumoral injection 2.0ml (660mg), 4.0ml (1220mg), 6.0ml (1880mg) and 8.0ml (2440mg) pts in female breast cancer patients.

Eligibility criteria:
inclusion criteria: * subjects are diagnosed as unsuitable for surgical operations or refuse to do so. * subject's performance status is classified as grade 0 to grade 3. estimated survival time should be longer than 6 months of time. * physical examinations show no serious functional disorders of the heart, liver, kidneys, or blood. * subjects were treated with radio or chemotherapy previously. a minimum of 2 to 3 months recovery time is required before treating with this investigational drug. * subject is diagnosed as intratracheal lesions with metastasized pulmonary cancer not suitable for surgery, or refuses to be operated. * subject should show lobular atelectasis with either complete or incomplete obstruction of the bronchi. * physical examinations should show no functional disorders of the heart, liver, kidneys, central nervous system, and blood. * subject performance status to be classified from grade 0 to grade 3, who can tolerate the fiberoptic bronchoscopy treatments. * in-patient is preferred. when subject is in satisfactory conditions, the out cpatient can also be enrolled in this trial. * two to three months recovery time is required for the subject has just received radio or chemotherapy. * emergency request, subjects with serious lobular atelectasis and almost complete obstruction of the bronchi. * with the aid of a tracheal intubation and the help of the respirator, pts may be intraumorally injected into the obstructed lesion via fiberoptic bronchoscopy outside of the tube, alongside of the intubation. exclusion criteria: * pregnant women and children will not be used as test subjects. * subjects with serious functional disorders of the heart, liver, kidneys, or blood will be excluded. * subjects who do not want to participate in the trial will not be used as test subjects. * subject does not agree to participate. * subject performance status is grade 4, and the one who does not want to tolerate the discomfort of the pts treatments via fiberoptic bronchscopy.